We have previously demonstrated the upregulation of BAFF and transitional B cells as a unique common pathway of current efficacious multiple sclerosis treatments, shedding new light on the failure of anti-BAFF trials, which also appeared promising in EAE (Dooley et al., 2016). The gene discussed is TNFSF13B; the disease is multiple sclerosis.